INT192687

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2006
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 1.42
Pain Relevance 0.08

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (PAX5) nucleus (PAX5) DNA binding (PAX5)
Anatomy Link Frequency
Urine 2
spine 1
PAX5 (Homo sapiens)
Pain Link Frequency Relevance Heat
Facet joint 3 96.56 Very High Very High Very High
fibrosis 1 63.48 Quite High
Inflammation 10 38.16 Quite Low
headache 64 37.84 Quite Low
backache 6 14.40 Low Low
cva 14 5.00 Very Low Very Low Very Low
corticosteroid 12 5.00 Very Low Very Low Very Low
withdrawal 9 5.00 Very Low Very Low Very Low
rheumatoid arthritis 6 5.00 Very Low Very Low Very Low
Potency 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Sclerosis 3 96.96 Very High Very High Very High
Hip Fractures 24 94.20 High High
Hypercalcemia 99 93.12 High High
Mycobacterial Infection 81 74.88 Quite High
Osteoporosis 294 70.96 Quite High
Endometrial Cancer 7 69.08 Quite High
Fibrosis 1 63.48 Quite High
Postmenopausal Osteoporosis 25 62.64 Quite High
Infection 11 55.52 Quite High
INFLAMMATION 10 38.16 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Urine NTx and BSAP remained suppressed with continuous alendronate, but increased by about 25% when treatment was discontinued although they remained below baseline for the 5 years of observation
Negative_regulation (suppressed) of BSAP in Urine
1) Confidence 0.40 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.10 Pain Relevance 0.05
These gains were similar to those seen in the dose response study (Liberman et al 1995) and were accompanied by a 52% decrease in bone specific alkaline phosphatase (BSAP) and a 74% decrease in urine N terminal propeptide of type 1 collagen (NTx).
Negative_regulation (decrease) of BSAP in urine
2) Confidence 0.29 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.12 Pain Relevance 0
In an age-adjusted logistic regression model, a 1 SD reduction in BSAP was associated with a 26% reduction in spine fractures (CI 13%–37%), an 11% reduction in non-spine fractures (CI 0%–22%) and a 39% reduction in hip fractures (CI 22%–54%).
Negative_regulation (reduction) of BSAP in spine associated with hip fractures
3) Confidence 0.25 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.18 Pain Relevance 0
We found that, compared with placebo, women randomized to intermittent ISMO at 20 mg had a 45.4% decrease in NTx (95% confidence interval [CI]: 25.8 to 64.9) and a 23.3% increase (95% CI: 8.9 to 37.8) in BSAP.
Negative_regulation (decrease) of BSAP
4) Confidence 0.20 Published 2006 Journal Trials Section Body Doc Link PMC1471803 Disease Relevance 0.07 Pain Relevance 0
Serum levels of BSAP remained stable for the first 2 weeks and then decreased in a dose-dependent manner, suggesting that the effect on bone formation is an indirect effect.
Negative_regulation (decreased) of BSAP
5) Confidence 0.11 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924518 Disease Relevance 0.16 Pain Relevance 0
Significant decreases in BSAP levels were observed with the two higher doses.
Negative_regulation (decreases) of BSAP
6) Confidence 0.11 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924518 Disease Relevance 0.15 Pain Relevance 0
Inhibition of BSAP occurred more slowly, reaching a nadir at 60 days in the 3.0 mg/kg group of about 30% below baseline.
Negative_regulation (Inhibition) of BSAP
7) Confidence 0.09 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924518 Disease Relevance 0.15 Pain Relevance 0
Inversely, and based on our luciferase reporter gene assays, the loss of the potential PAX5, AHR and ARNT transcription factor binding sites predicted for the IRGM variant ?
Negative_regulation (loss) of PAX5
8) Confidence 0.09 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2735778 Disease Relevance 0.31 Pain Relevance 0
There were no significant reported decreases in serum bone-specific alkaline phosphatase (BSAP) with 14 days of lasofoxifene treatment.
Neg (no) Negative_regulation (decreases) of BSAP
9) Confidence 0.03 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773750 Disease Relevance 0.20 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox